Every 10-Q that Orthofix Medical Inc. (OFIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OFIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OFIX filings page.
Orthofix Medical (OFIX) filed its Q3 2025 10‑Q reporting net sales of $205.6 million, up 4.6% year over year, and a net loss of $22.8 million (basic and diluted EPS $(0.57)). Gross margin expanded to 72.2% from 68.7%, driven by lower cost of sales. Bone Growth Therapies rose 5.7% to $61.2 million; Global Orthopedics grew 10.1% to $33.6 million. Pro forma adjusted EBITDA was $24.6 million, and management noted seven consecutive quarters of adjusted EBITDA margin expansion with positive free cash flow of $2.5 million in the quarter.
Cash and cash equivalents were $62.9 million with long‑term debt of $157.2 million. The Lattus contingent consideration declined to $7.3 million after a $6.33 million installment. The company accrued $18.3 million related to former executive arbitration matters and recorded an IMDP accrual of $10.3 million. Shares outstanding were 39.6 million as of October 31, 2025.